or
forgot password

Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Cervical Cancer

Thank you

Trial Information

Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer

Inclusion Criteria


Inclusion criteria:

- >18 years old

- with biopsy-proven squamous, adenocarcinoma or adenosquamous cervical cancer

- no history of prior pelvic radiation and should be able to receive chemoradiation

- non-pregnant women who have not previously undergone a hysterectomy, as that would
have removed the cervix.

- able to give informed consent

Exclusion criteria:

- Subjects whose tumors are not FDG avid on the pre-therapy PET.

- Allergy or inability to receive iodinated CT contrast

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Cross-Sectional

Outcome Measure:

Measure perfusion in primary cervical tumors using perfusion CT.

Outcome Description:

Treatment response will be assessed using a post-treatment FDG-PET/CT to evaluate for complete response, persistent disease or new disease. The association between pre-treatment perfusion CT parameters and response on the post-treatment FDG-PET/CT will be analyzed.

Outcome Time Frame:

3-6 months

Safety Issue:

No

Principal Investigator

Elizabeth Kidd, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

GYNCVX0003

NCT ID:

NCT01805141

Start Date:

March 2013

Completion Date:

June 2016

Related Keywords:

  • Cervical Cancer
  • Cervix Uteri
  • Uterine Cervical Neoplasms

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317